Moreover, CRELD2 is characterized as an early, sensitive, non-invasive, and mechanistic biomarker in the urine in various ER stress-mediated kidney diseases, including hereditary NS, ischemic AKI, and autosomal dominant tubulointerstitial kidney disease (ADTKD), due to mutations in the UMOD gene encoding uromodulin (72, 125–127). This evidence concerns the gene UMOD and autosomal dominant medullary cystic kidney disease with or without hyperuricemia.